Article
Oncology
Xiaozhen Zhang, Mengyi Lao, Jian Xu, Yi Duan, Hanshen Yang, Muchun Li, Honggang Ying, Lihong He, Kang Sun, Chengxiang Guo, Wen Chen, Haitao Jiang, Xiaoyu Zhang, Xueli Bai, Tingbo Liang
Summary: Combination therapy with anti-TNFR2 and anti-PD-L1 can eradicate tumors, prolong overall survival, and activate robust antitumor immune response in advanced pancreatic ductal adenocarcinoma.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Richard S. P. Huang, Brennan Decker, Karthikeyan Murugesan, Matthew Hiemenz, Douglas A. Mata, Gerald Li, James Creeden, Shakti H. Ramkissoon, Jeffrey S. Ross
Summary: The study found low prevalence of non-amplification short variants (SV) mutations in CD274, with mutation types and rates varying by tumor type. Specific mutation types may affect the expression level of PD-L1 protein and potentially function as resistance biomarkers in ICPI therapy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Richard S. P. Huang, Karthikeyan Murugesan, Meagan Montesion, Dean C. Pavlick, Douglas A. Mata, Matthew C. Hiemenz, Brennan Decker, Garrett Frampton, Lee A. Albacker, Jeffrey S. Ross
Summary: The study analyzed a large cohort of solid tumor cases to investigate CD274 copy-number changes and their correlation with PD-L1 protein expression. The prevalence of CD274 copy-number changes varied across different tumor types and was found to be significantly associated with PD-L1 positivity in certain tumor types, indicating its potential as a biomarker for immune checkpoint inhibitor therapy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Shunichi Taki, Kohei Matsuoka, Yuko Nishinaga, Kazuomi Takahashi, Hirotoshi Yasui, Chiaki Koike, Misae Shimizu, Mitsuo Sato, Kazuhide Sato
Summary: The study modified photoimmunotherapy by targeting PD-L1 to enhance anticancer immune system. The therapy showed limited effect on tumor cells in vitro but induced sufficient antitumor effects in vivo, mediated by the 'photoimmuno' effect and antitumor immunity augmentation. The local PD-L1-targeted NIR-PIT enhanced the antitumor immune reaction through direct photonecrotic effect, providing an alternative approach to targeted cancer immunotherapy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Sen Yan, Han Zeng, Kaifeng Jin, Fei Shao, Zhaopei Liu, Yuan Chang, Yiwei Wang, Yu Zhu, Zewei Wang, Le Xu, Jiejie Xu
Summary: The expression of NKG2A and PD-L1 together can be used as a combinatorial biomarker to predict the therapeutic response to immune checkpoint blockade in patients with muscle-invasive bladder cancer.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Review
Oncology
Carolina Mathias, Vanessa Nascimento Kozak, Jessica Maria Magno, Suelen Cristina Soares Baal, Victor Henrique Apolonio dos Santos, Enilze Maria de Souza Fonseca Ribeiro, Daniela Fiori Gradia, Mauro Antonio Alves Castro, Jaqueline Carvalho de Oliveira
Summary: In this article, we review the role of long non-coding RNAs (lncRNAs) in the regulation of the PD-1/PD-L1 pathway and in defining immune-related prognostic signatures in various types of tumors. We also identify two lncRNAs, UCA1 and HCP5, which have not yet been studied in the context of the tumoral immune response in breast cancer, but may have potential as biomarkers for the response to immune checkpoint inhibitors.
Article
Oncology
Yangyang Zhang, Lingxiu Zeng, Meng Wang, Zhenwei Yang, Hailin Zhang, Liping Gao, Ranran Zhang, Jialong Liu, Wenqing Shan, Ying Chang, Lan Liu, Qiu Zhao, Yong Li, Jing Liu
Summary: The study found that RIG-I plays an important role in the immunotherapy of colon cancer by maintaining the stability of PD-L1 to promote immune evasion. Silencing RIG-I increases the sensitivity of tumor cells to T cell killing and slows down the growth of colon tumors. High expression of RIG-I promotes tumor progression and enhances the sensitivity to PD-1 therapy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Review
Oncology
Laure Chardin, Alexandra Leary
Summary: Ovarian cancer is a highly lethal gynecologic malignancy with a high recurrence rate, despite many patients responding effectively to current treatments. In order to improve outcomes, further research into the immune microenvironment and the development of effective therapies are urgently needed.
FRONTIERS IN ONCOLOGY
(2021)
Review
Oncology
Zi Yin, Min Yu, Tingting Ma, Chuanzhao Zhang, Shanzhou Huang, Mohammad Reza Karimzadeh, Amir Abaas Momtazi-Borojeni, Sheng Chen
Summary: Exosomes, specifically those derived from cancer cells, contain immunosuppressive proteins such as PD-L1, which can hinder immune responses and promote tumor progression. Blocking the interaction between PD-1 and PD-L1 can enhance the efficacy of cancer treatment by restoring anti-tumor immunity.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Chunwan Lu, Zhuoqi Liu, John D. Klement, Dafeng Yang, Alyssa D. Merting, Dakota Poschel, Thomas Albers, Jennifer L. Waller, Huidong Shi, Kebin Liu
Summary: Despite the expression of PD-L1 in tumor cells and T lymphocytes, human pancreatic cancer does not respond to immune checkpoint inhibitor immunotherapy. Epigenome dysregulation leads to T cell exhaustion and non-response to immunotherapy. OPN compensates for the function of PD-L1 in promoting immune escape in pancreatic cancer.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Hena Khalique, Richard Baugh, Arthur Dyer, Eleanor M. Scott, Sally Frost, Sarah Larkin, Janet Lei-Rossmann, Leonard W. Seymour
Summary: PD-L1 BiTE is an effective immunotherapeutic approach to kill PD-L1-positive tumor cells and macrophages while leaving T cells unharmed. This approach activates endogenous T cells within malignant ascites, generates a proinflammatory response, and eliminates cells promoting tumor progression. Using an oncolytic virus for local expression of PD-L1 BiTE also prevents 'on-target off-tumor' systemic toxicities and harnesses immunosuppressive protumor conditions to augment immunotherapy in immunologically 'cold' clinical cancers.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Review
Immunology
Xuan Zhao, Yulin Bao, Bi Meng, Zijian Xu, Sijin Li, Xu Wang, Rui Hou, Wen Ma, Dan Liu, Junnian Zheng, Ming Shi
Summary: Developing biomarkers for predicting the efficacy of immune checkpoint inhibitor therapies is important for avoiding side effects and economic burden. Current assays evaluating PD-L1 expression are imperfect, but recent studies are advancing the methodologies to improve accuracy. This includes standardization of immunohistochemistry tests and the use of novel in vivo probes and liquid biopsy. Considering PD-L1 expression on non-tumor cells and utilizing artificial intelligence can further enhance the predictive accuracy of PD-L1 as a biomarker.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Tianyu Tang, Xing Huang, Gang Zhang, Minghao Lu, Zhengtao Hong, Meng Wang, Junming Huang, Xiao Zhi, Tingbo Liang
Summary: This study demonstrates that LTX-315 can enhance lymphocyte infiltration and induce an antitumor immune response by inhibiting PD-L1 expression in pancreatic tumors. ATP11B is identified as a potential target of LTX-315 and a critical regulator in maintaining PD-L1 expression.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Medicine, Research & Experimental
Yingke Zhou, Xin Jin, Haixin Yu, Gengdu Qin, Penglin Pan, Jingyuan Zhao, Taoyu Chen, Xueyi Liang, Yan Sun, Bo Wang, Dianyun Ren, Shikai Zhu, Heshui Wu
Summary: This study reveals the role of HDAC5 in regulating the NF-KB signaling pathway and antitumor immune responses in PDAC. HDAC5 downregulation is associated with favorable prognosis in PDAC patients. HDAC5 regulates PD-L1 expression by interacting with NF-KB p65 and its inhibition sensitizes PDAC tumors to immune checkpoint blockade therapy.
Article
Oncology
Davide Melisi, Do-Youn Oh, Antoine Hollebecque, Emiliano Calvo, Anna Varghese, Erkut Borazanci, Teresa Macarulla, Valeria Merz, Camilla Zecchetto, Yumin Zhao, Ivelina Gueorguieva, Michael Man, Leena Gandhi, Shawn T. Estrem, Karim A. Benhadji, Mark C. Lanasa, Emin Avsar, Susan C. Guba, Rocio Garcia-Carbonero
Summary: The study assessed the safety, efficacy, and pharmacokinetics of the combination therapy of galunisertib and durvalumab in patients with recurrent/refractory metastatic pancreatic cancer. The results showed tolerability of the combination therapy, with limited clinical activity observed. Further studies in patients in earlier lines of treatment or with predictive biomarkers of TGF beta inhibition may be more suitable.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Review
Medicine, Research & Experimental
Luman Liu, Prakash G. Kshirsagar, Shailendra K. Gautam, Mansi Gulati, Emad Wafa, John C. Christiansen, Brianna M. White, Surya K. Mallapragada, Michael J. Wannemuehler, Sushil Kumar, Joyce C. Solheim, Surinder K. Batra, Aliasger K. Salem, Balaji Narasimhan, Maneesh Jain
Summary: Pancreatic tumors are difficult to treat due to their highly fibrotic and immunosuppressive nature. Nanotechnology offers promising solutions by providing improved drug delivery and immunotherapy-based approaches. This review highlights the potential of nanoscale strategies for treating pancreatic tumors and discusses future research directions.
Article
Materials Science, Biomaterials
Alaric C. Siddoway, David Verhoeven, Kathleen A. Ross, Michael J. Wannemuehler, Surya K. Mallapragada, Balaji Narasimhan
Summary: Seasonal influenza A virus infections cause significant damage to health and economic resources each year. The current vaccines provide inadequate protection and require annual reformulation. This study explores the use of a recombinant equine H3N8 hemagglutinin trimer as a potential vaccine antigen, combined with nanoadjuvants, to develop a universal influenza A virus nanovaccine.
ACS BIOMATERIALS SCIENCE & ENGINEERING
(2022)
Article
Environmental Sciences
Alexander Kmoch, Desalew Meseret Moges, Mahdiyeh Sepehrar, Balaji Narasimhan, Evelyn Uuemaa
Summary: This study investigates the impact of input data on the performance of the SWAT model. The results show that using high-resolution local data for soil does not necessarily improve model performance, while in the case of land use data, using local high-resolution data can enhance model performance.
Article
Microbiology
Kasturi Banerjee, Michael P. Motley, Camila Boniche-Alfaro, Somanon Bhattacharya, Raj Shah, Andrew Ardizzone, Bettina C. Fries
Summary: In this study, we present in vitro and in vivo data demonstrating the cross-protective efficacy of the wzi50 CPS-specific monoclonal antibody MAb 24D11 against three prominent win types (wzi29, wzi154, and wzi50) of the carbapenem-resistant clonal group CG258. In a murine pulmonary infection model, MAb 24D11 reduced bacterial lung burden and dissemination to other organs even if administered 4 h postinfection, and its protective efficacy was also observed in neutropenic mice, highlighting its potential value in clinical settings.
MICROBIOLOGY SPECTRUM
(2022)
Article
Oncology
Shailendra K. Gautam, Vipin Dalal, Balasrinivasa R. Sajja, Suprit Gupta, Mansi Gulati, Nidhi V. Dwivedi, Abhijit Aithal, Jesse L. Cox, Satyanarayana Rachagani, Yutong Liu, Vincent Chung, Ravi Salgia, Surinder K. Batra, Maneesh Jain
Summary: The hypovascular and desmoplastic tumor microenvironment in pancreatic cancer restricts drug delivery. This study found that targeting the ET-axis can improve tumor perfusion and macromolecular transport, enhancing the delivery of therapeutic agents.
Article
Virology
Laura M. Stephens, Kathleen A. Ross, Jason S. McLellan, Balaji Narasimhan, Steven M. Varga
Summary: RSV infection causes significant infections and deaths in children and elderly adults each year. There is currently no licensed vaccine for RSV prevention. This study developed a vaccine candidate, RSVNanoVax, which provided long-term protection and immunity in outbred Swiss Webster mice.
JOURNAL OF VIROLOGY
(2022)
Article
Oncology
Shailendra K. Gautam, Soumi Basu, Abhijit Aithal, Nidhi . Dwivedi, Mansi Gulati, Maneesh Jain
Summary: Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy with high resistance to chemotherapy. Poorly immunogenic pancreatic tumors make immunotherapy ineffective. Chemokines play an important role in PDAC and combination therapy shows promising results.
SEMINARS IN CANCER BIOLOGY
(2022)
Article
Environmental Sciences
K. Sangeetha, Balaji Narasimhan, R. Srinivasan
Summary: This study aims to test the concept of integrating a distributed hydrologic model with an AEM model at the same spatial units, primarily focusing on the interaction between a shallow unconfined aquifer and surface water and groundwater. The results of the study show the potential application of SWAT-AEM coupling in regions with significant SW-GW interactions.
Article
Agriculture, Dairy & Animal Science
Andrew K. Curtis, Douglas E. Jones, Michael Kleinhenz, Shawnee Montgomery, Miriam Martin, Mikaela Weeder, Alyssa Leslie, Balaji Narasimhan, Sean Kelly, Drew R. Magstadt, Alfredo Colina, Johann F. Coetzee
Summary: Male cattle are often castrated to reduce aggression and unwanted pregnancies, but this procedure causes pain and risks like hemorrhage and infection. Immunocastration using vaccines offers a less painful alternative, but current options require multiple doses. A single-dose implantable immunocastration vaccine was evaluated, showing promising results in reducing fertility and potentially improving animal welfare during livestock management.
Article
Immunology
Yashdeep Phanse, Supraja Puttamreddy, Duan Loy, Julia Vela Ramirez, Kathleen A. Ross, Ignacio Alvarez-Castro, Mark Mogler, Scott Broderick, Krishna Rajan, Balaji Narasimhan, Lyric C. Bartholomay
Summary: In the past 15 years, crustacean fisheries have suffered significant economic losses due to viral diseases. No effective measures are available to prevent or control these outbreaks. However, a double-stranded RNA-based nanovaccine shows promise for controlling infectious diseases in aquaculture.
Article
Engineering, Civil
P. Yaswanth, B. Arul Malar Kannan, V. M. Bindhu, C. Balaji, Balaji Narasimhan
Summary: This study evaluates the accuracy of Remote Sensing Rainfall Products (RRPs) in urban hydrologic predictions. The results show that RRPs can accurately simulate the rising and recession portion of flood hydrographs, but with a bias in peak discharge. Two approaches, disaggregation and bias adjustment, using satellite rainfall estimates are found to improve flood hydrograph simulations. The disaggregation approach overcomes the insufficiency of sub-daily rainfall observations, while bias adjusted radar rainfall data performs the best.
WATER RESOURCES MANAGEMENT
(2023)
Article
Geriatrics & Gerontology
Ananya Ananya, Kaitlyn G. G. Holden, Zhiling Gu, Dan Nettleton, Surya K. K. Mallapragada, Michael J. J. Wannemuehler, Marian L. L. Kohut, Balaji Narasimhan
Summary: Inflammaging, a factor contributing to immunosenescence, reduces vaccine effectiveness. This study demonstrates that combining appropriate adjuvants with nanoparticles and micelles can induce immune responses in older adults while reducing inflammation. These findings have important implications for designing next generation mucosal vaccines for older adults.
Meeting Abstract
Immunology
Teresia Maina, Elizabeth Grego, Balaji Narasimhan, Randy E. Sacco, Jodi L. McGill
JOURNAL OF IMMUNOLOGY
(2022)
Meeting Abstract
Immunology
Laura Stephens, Kathleen A. Ross, Jason S. McLellan, Balaji Narasimhan, Steven M. Varga
JOURNAL OF IMMUNOLOGY
(2022)
Article
Infectious Diseases
John J. Psonis, Yamil Michelen, Kasturi Banerjee, Bettina C. Fries, Sutthichai Sae-Tia
Summary: This article reports a case of pyogenic liver abscess caused by HVkp hypervirulent Klebsiella pneumoniae strain in a non-Asian region. The strain is uncommon in North America, but the recent emergence of multidrug resistance and spreading poses a serious threat to public health.
JOURNAL OF GLOBAL INFECTIOUS DISEASES
(2022)
Review
Oncology
Xinru Zhou, Yin Jia, Chuanbin Mao, Shanrong Liu
Summary: Small extracellular vesicles (sEVs), such as exosomes, have emerged as crucial targets for liquid biopsy and promising drug delivery vehicles in tumor progression. They can serve as biomarkers for tumor diagnosis and as drug carriers for cancer treatment.
Article
Oncology
Ruochan Chen, Ju Zhu, Xiao Zhong, Jie Li, Rui Kang, Daolin Tang
Summary: The interplay between autophagy and apoptosis plays a crucial role in tumorigenesis and cancer therapy, with HMGB1 serving as a key regulator in these processes.
Article
Oncology
Zongfu Pan, Xixuan Lu, Tong Xu, Jinming Chen, Lisha Bao, Ying Li, Yingying Gong, Yulu Che, Xiaozhou Zou, Zhuo Tan, Ping Huang, Minghua Ge
Summary: This study uncovered the emerging role of HN1 in promoting dedifferentiation of anaplastic thyroid cancer (ATC) cells. HN1 negatively regulated the thyroid differentiation markers and had an inhibitory effect on the transcriptional activation of CTCF, thereby influencing the chromatin accessibility of thyroid differentiation genes.
Article
Oncology
Yi Qin, Shengjun Xiong, Jun Ren, Gautam Sethi
Summary: Autophagy plays an important regulatory role in glioblastoma, and its dysregulation can lead to drug resistance and radioresistance. It also affects stem cell characteristics, overall growth, and metastasis. Therefore, autophagy is a promising target for glioblastoma therapy.
Article
Oncology
Katsuya Nagaoka, Xuewei Bai, Dan Liu, Kevin Cao, Joud Mulla, Chengcheng Ji, Hongze Chen, Muhammad Azhar Nisar, Amalia Bay, William Mueller, Grace Hildebrand, Jin-Song Gao, Shaolei Lu, Hiroko Setoyama, Yasuhito Tanaka, Jack R. Wands, Chiung-Kuei Huang
Summary: This study found that serum 2-OG levels in cholangiocarcinoma patients are associated with the effectiveness of chemotherapy. Patients with progressive disease showed significantly higher levels of serum 2-OG compared to stable disease and partial response patients. The study also revealed that overexpression of ASPH mimics the effects of 2-OG, and knockdown of ASPH improves chemotherapy. Targeting ASPH enhances the effects of chemotherapy by modulating ATM and ATR, two key regulators of DDRs.